Checkmate Pharmaceuticals Operating Income

The latest operating income for CMPI is $-63M as of March 2022. That compares with $-43M in the prior-year period — down 45.9% year over year. Investors often review this figure alongside Checkmate Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, CMPI's operating income moved from $-43M to $-63M — a 45.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Checkmate Pharmaceuticals's operating scale or balance-sheet position.

A operating income figure of $-63M for CMPI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CMPI's operating income ($-63M), review year-over-year change from $-43M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Checkmate Pharmaceuticals's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.